TLSI (TriSalus Life Sciences) 3-Year Revenue Growth Rate : -65.00% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences 3-Year Revenue Growth Rate?

TriSalus Life Sciences's Revenue per Share for the three months ended in Dec. 2024 was $0.30.

During the past 12 months, TriSalus Life Sciences's average Revenue per Share Growth Rate was -41.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -65.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 4 years, the highest 3-Year average Revenue per Share Growth Rate of TriSalus Life Sciences was -65.00% per year. The lowest was -65.00% per year. And the median was -65.00% per year.

Competitive Comparison of TriSalus Life Sciences's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, TriSalus Life Sciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TriSalus Life Sciences's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where TriSalus Life Sciences's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

TriSalus Life Sciences 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

TriSalus Life Sciences (NAS:TLSI) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

TriSalus Life Sciences 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

TriSalus Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

6272 W. 91st Avenue, Westminster, CO, USA, 80031

Website

https://www.trisaluslifesci.com

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines?Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Executives

Mary T Szela	director, officer: CEO and President	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Sean Murphy	director, officer: Chief Financial Officer	C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Equity Ab Frankenius	10 percent owner	BOX 984, BORAS V7 SE-501 10
Arjun Jj Desai	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mats Wahlstrom	director, 10 percent owner	500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Bryan F. Cox	officer: Chief Scientific & Manufact.	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
George Kelly Martin	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jodi Devlin	officer: President, Therapeutics	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Kerry R Hicks	director	C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228
James Alecxih	officer: President, Device Technology	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Anil K. Singhal	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz	officer: Chief Medical Officer	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Von Eschenbach Andrew C.	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Richard Marshak	officer: Sr.VP, Corp. Dev. & Strategy	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jennifer Stevens	officer: Chief Regulatory Officer	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031